{"id":"W4388047700","doi":"10.1136/jitc-2023-sitc2023.0609","title":"609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Antibody; Pharmacokinetics; In vitro; Monoclonal antibody; Pharmacology; Receptor; Cancer research; Cell cycle; Medicine; Chemistry; Internal medicine; Immunology; Cancer; Biochemistry","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006644913,0.0005716008,0.0007300483,0.0003574392,0.0002496968,0.0006452051,0.0003553505,0.0005379044,0.003492431],"category_scores_gemma":[0.0003619398,0.0002519603,0.0004654604,0.0002482268,0.0003125783,0.0002683413,0.0001888594,0.001327802,0.0008000759],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007770901,"about_ca_system_score_gemma":0.001047858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001170099,"about_ca_topic_score_gemma":0.002763376,"domain_scores_codex":[0.9998065,0.00007704044,0.000008280409,0.00003379858,0.00003141317,0.00004298743],"domain_scores_gemma":[0.9998273,0.00002873955,0.00003071148,0.00002020979,0.00001833139,0.00007464452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1801362,0.07828139,0.01423351,0.0004509573,0.0004613583,0.0003211777,0.0004188728,0.01103539,0.4673522,0.001041961,0.01305595,0.2332111],"study_design_scores_gemma":[0.08563678,0.6973518,0.04330928,0.00005850607,0.0004582043,0.0007629382,0.0001469803,0.01019675,0.1344937,0.00092993,0.02658405,0.00007109565],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907343,0.0009830631,0.001148998,0.0002304293,0.00003918958,0.001896867,0.001346562,0.0001520406,0.00346847],"genre_scores_gemma":[0.9892117,0.00069156,0.003181511,0.0003976896,0.00004568664,0.001488935,0.001767072,0.00007162289,0.003144265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003492431,"threshold_uncertainty_score":0.0116834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0101685356109609,"score_gpt":0.2704615126143873,"score_spread":0.2602929770034264,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}